Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Ovarian Reserve and Stimulation Response Before Chemotherapy Treatment in Breast Cancer Patients Undergoing Fertility Preservation: A Historical Cohort Study Publisher Pubmed



Jahangiri N ; Ghaffari F ; Hafezi M ; Ebrahimi B ; Vesali S ; Olfatbakhsh A ; Hosseini S
Authors

Source: Journal of Ovarian Research Published:2025


Abstract

Background: Fertility preservation is an important aspect of care for breast cancer patients. This study was designed to compare the ovarian function including ovarian reserve and ovarian stimulation response in breast cancer patients undergoing controlled ovarian stimulation (COS) for fertility preservation before chemotherapy, and oocyte donors as healthy women. Methods: This historical cohort study enrolled 78 breast cancer patients who underwent COS for fertility preservation between April 2014 and March 2022 at the Infertility Center of Royan Institute, Tehran, Iran. Sixty-six healthy oocyte donors were included as a control group during the same time period. The inclusion criteria were female patients aged ≤ 35 years, with confirmed breast cancer with indication of chemotherapy, who were elected for ovarian stimulation before chemotherapy for oocyte retrieval. Women with the diagnosis of poor ovarian response, polycystic ovary syndrome, severe male factor infertility, endometriosis, and those who used oral contraceptives excluded from the study. Main outcome measure was retrieved total number of mature oocytes. Results: The mean age was significantly higher and mean body mass index was significantly lower in the breast cancer group than in the oocyte donor group. There were also significant differences between groups in terms of hormonal profiles of luteinizing hormone and anti-mullerian hormone (AMH), gonadotropin starting dose, total dose of gonadotropin used and oocyte maturation rate. Based on the results, there was a significant correlation between Metaphase II and AMH in breast cancer group (r = 626; P < 0.001). Conclusion: It appears that patients with cancer experience diminished ovarian reserve prior to cancer treatment. Further prospective studies with larger sample sizes are recommended. Clinical trial number: Not applicable. © 2025 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. Integrating Salivary Biomarkers Cst4 and Mir-223 With Health-Related Factors for Gastric Cancer Detection and Risk Assessment, Clinical Medicine Insights: Oncology (2025)
2. Investigating Socioeconomic Inequality in the Incidence of Breast Cancer in Iran: Interprovincial Analysis and Comparison, Scientific Journal of Kurdistan University of Medical Sciences (2025)
3. National and Subnational Burden of Female and Male Breast Cancer and Risk Factors in Iran From 1990 to 2019: Results From the Global Burden of Disease Study 2019, Breast Cancer Research (2023)
Experts (# of related papers)
View all Related Experts
Farshad Farzadfar (4)
Reza Malekzadeh (3)
Other Related Docs
4. Evaluation of Cstb and Dmbt1 Expression in Saliva of Gastric Cancer Patients and Controls, BMC Cancer (2022)
5. Mortality Rates and Years of Life Lost Due to Cancer in Iran: Analysis of Data From the National Death Registration System, 2016, International Journal of Cancer Management (2022)
6. Functions, Mechanisms, and Clinical Applications of Lncrna Linc00857 in Cancer Pathogenesis, Human Cell (2023)
7. Advances in Therapeutic Targeting of Immune Checkpoints Receptors Within the Cd96-Tigit Axis: Clinical Implications and Future Perspectives, Expert Review of Clinical Immunology (2022)
8. The Burden of Prostate Cancer in North Africa and Middle East, 1990–2019: Findings From the Global Burden of Disease Study, Frontiers in Oncology (2022)
9. Building a Cancer Biobank in a Low-Resource Setting in Northern Iran: The Golestan Cancer Biobank, Archives of Iranian Medicine (2021)
10. Global, Regional and National Burden of Bladder Cancer and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019, BMJ Global Health (2021)
11. Physical and Functional Evaluations in Oncological Patients Elective to Medium and Large Operations, Supportive Care in Cancer (2023)
12. Burden of Thyroid Cancer in North Africa and Middle East 1990–2019, Frontiers in Oncology (2022)
13. Curcumin and Its Novel Formulations for the Treatment of Hepatocellular Carcinoma: New Trends and Future Perspectives in Cancer Therapy, Journal of Functional Foods (2023)
14. The Role of Non-Coding Rnas in the Regulation of Cell Death Pathways in Melanoma, Discover Oncology (2025)
15. A Narrative Review on Therapeutic Potential of Naringenin in Colorectal Cancer: Focusing on Molecular and Biochemical Processes, Cell Biochemistry and Function (2024)
16. Using a Social Marketing Approach to Increase the Pap-Smear Test Uptake: Randomized Controlled Trial Among Women Residing in Urban Region, BMC Women's Health (2025)
17. Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities, Advanced Pharmaceutical Bulletin (2024)
18. Impact of Smoking and Opium Cessation on Gastrointestinal Cancer Risk: A 15-Year Longitudinal Study in Golestan Cohort, Scientific Reports (2025)
19. The Role of Her2 Alterations in Clinicopathological and Molecular Characteristics of Breast Cancer and Her2-Targeted Therapies: A Comprehensive Review, Medical Oncology (2022)
20. Association of Imaging and Pathological Findings of Breast Cancer in Very Young Women: Report of a Twenty-Year Retrospective Study, Clinical Imaging (2024)